logo

TECH

Bio-Techne
--
--(--)
Market Open: --
--
--(--)
Post-Market: --
Signals Analysis
Buy signal 4
Sell signal 1
ample liquidity
High Gross Profit Margin
Upward Gap
High Cash/net Profit Ratio
EPS Below Expectations

Key Stats

--DAY`S RANGE--
--52 WK RANGE--
--
--
--
--
--
--
--
--
--
--
--
--
--
--
--
--
--
--
--
--

About TECH

Bio-Techne Corporation

A leading developer and manufacturer of biotechnology reagents and instruments for research, diagnostics, and pharmaceutical applications

Life Science Tools and Services
07/17/1981
05/12/1989
NASDAQ Stock Exchange
3100
06-30
Common stock
614 McKinley Place N.E., Minneapolis, MN 55413
--
Bio-Techne Corporation was founded in Minnesota on July 17, 1981. Bio-Techne and its subsidiaries jointly operate businesses that develop, manufacture and sell life science reagents, instruments and services for the global research, diagnostic and bioprocessing markets. With its deep product portfolio and applied expertise, the company sells components of scientific investigations of biological processes and molecular diagnosis, revealing the nature, diagnosis, etiology and progression of specific diseases.

Company Financials

EPS

TECH has released its 2025 Q2 earnings. EPS was reported at 0.42, versus the expected 0.38, beating expectations. The chart below visualizes how TECH has performed over recent quarters, highlighting trends in earnings surprises.

Revenue & Expenses

TECH has released its 2025 Q2 earnings report, with revenue of 297.03M, reflecting a YoY change of 8.96%, and net profit of 34.89M, showing a YoY change of 27.03%. The Sankey diagram below clearly presents TECH’s revenue sources and cost distribution.

Forecast

Wall Street Opinions

Price Target

Volume Profile

Trade Flow Insight

Seasonals

Community Forum

Loading...

Related News

No articles available

Related Symbols

You can ask Aime